On the same day AstraZeneca avoided a Food and Drug Administration ban on Crestor, the pharmaceutical company received a warning letter from the agency asking that it cease advertising on the
cholesterol-fighting drug because it has made "false or misleading claims regarding the superiority of Crestor" in a series of direct-to-consumer ads.
Read the whole story at AdAge.com, March 15, 2005 »